Breast cancer chemoprevention pharmacogenomics: Deep sequencing and functional genomics of the ZNF423 and CTSO genes

Pharmacogenetics: Sequencing finds DNA variants affecting chemoprevention response DNA sequencing has revealed genetic variants that explain inherited variation in responses to preventative drug therapy for breast cancer. Richard Weinshilboum from the Mayo Clinic in Rochester, Minnesota, USA, and co...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Duan Liu, Ming-Fen Ho, Daniel J. Schaid, Steven E. Scherer, Krishna Kalari, Mohan Liu, Joanna Biernacka, Vivien Yee, Jared Evans, Erin Carlson, Matthew P. Goetz, Michiaki Kubo, D. Lawrence Wickerham, Liewei Wang, James N. Ingle, Richard M. Weinshilboum
Formato: article
Lenguaje:EN
Publicado: Nature Portfolio 2017
Materias:
Acceso en línea:https://doaj.org/article/56c8ccff590441f0a7e69f6365d4c7bb
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
Descripción
Sumario:Pharmacogenetics: Sequencing finds DNA variants affecting chemoprevention response DNA sequencing has revealed genetic variants that explain inherited variation in responses to preventative drug therapy for breast cancer. Richard Weinshilboum from the Mayo Clinic in Rochester, Minnesota, USA, and colleagues previously showed that genetic variations in or near two genes—ZNF423 and CTSO—affected how well the drugs tamoxifen and raloxifene reduced the rate of breast cancer occurrence. Building on that finding, Weinshilboum’s team has now sequenced these two genes in 199 patients who developed breast cancer during chemopreventative drug therapy and 201 patients who did not. They identified around 4000 single-nucleotide polymorphisms across each gene, 21 of which were close to estrogen response element (ERE) motifs to which ERα binds. Functional studies pointed to molecular ways in which some of these gene variants alter drug activity.